Gilead tracks five years of HIV grant giving in hard-hit US South, and doubles down on new approaches

Beth Snyder Bulik

Senior Editor

Gilead Sciences is now halfway through its 10-year pledge in the US southern states to tackle HIV through community grants, and looking back while also …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead tracks five years of HIV grant giving in hard-hit US South, and doubles down on new approaches

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Gilead tracks five years of HIV grant giv­ing in hard-hit US South, and dou­bles down on new ap­proach­es

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Gilead tracks five years of HIV grant giving in hard-hit US South, and doubles down on new approaches